Start here if you're new
what it is
UnitedHealth sells insurance and runs pharmacy, care, and data services.
how it gets paid
Last year UnitedHealth Group reported $447.6B in consolidated revenues. UnitedHealthcare segment revenues were $344.9B (+16% YoY); Optum segment revenues were $270.6B (+7%). Consolidated total is lower than the sum because of eliminations between segments.
why it's growing
Revenue grew 12% last year to $447.6B. The 2026 outlook is for revenues greater than $439.0B with adjusted EPS greater than $17.75.
what just happened
Q4 2025 adjusted EPS was $2.11; reported GAAP EPS was $0.01 for the quarter after restructuring, cyber, and related charges. Full-year 2025 adjusted EPS was $16.35 on $447.6B revenue.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
90/100 earnings predictability — you can trust these numbers
18.0x trailing p/e — the market's not buying it — or you found a deal
3.4% dividend yield — cash in your pocket every quarter
14.0% return on capital — nothing to write home about
xvary composite: 62/100 — average
What they do
UnitedHealth sells insurance and runs pharmacy, care, and data services.
Your doctor bill, your prescriptions, and your claims can all pass through one system. For UnitedHealthcare, the reported medical care ratio was 89.1% in 2025 (adjusted 88.9%)—i.e., the share of premiums used for care. That is not “gross margin,” but it is the lever that moves the insurance economics.
How they make money
$447.6B
consolidated annual revenue · +12% YoY · segment lines below are as reported in FY 2025 earnings and are not additive to consolidated (intersegment eliminations)
UnitedHealthcare (segment)
$344.9B
+16%
Optum (segment)
$270.6B
+7%
The products that matter
managed care membership engine
UnitedHealthcare
50M+ members
this is the insurance core. 50M+ members give you the scale to spread risk, negotiate rates, and absorb fixed costs across a national base.
scale moat
care delivery, pharmacy, and analytics
Optum
part of a $447.6B system
the segment split is thin on this page, and that is a real limitation. what you do know is that optum sits inside a company generating $447.6B in annual revenue, which is why any regulatory or cost shock hits more than one profit stream at once.
integration edge
Key numbers
18.0x
trailing p/e
You are paying 18 times last year's profit. That is not cheap for a company with 1.0% projected earnings growth.
3.4%
dividend yield
You get $3.40 a year for every $100 invested. That cushions a stock that just got re-rated lower.
89.1%
UHC medical care ratio (reported)
Reported MCR 89.1%; adjusted 88.9% in FY 2025 materials. This is a premium-benefit metric for the insurance segment—not corporate gross margin.
14.0%
return on capital
The business earned 14 cents for every dollar it put to work. That is decent for a giant with this scale.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 55 / 100
- long-term debt $72.3B (21% of capital)
- net profit margin 4.5% — keeps 4 cents of every dollar in revenue
- return on equity 20% — $0.20 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in UNH 3 years ago → it's now worth $6,250.
The index would have given you $13,880.
source: institutional data · total return
What just happened
adjusted eps in-line / beat
Q4 2025 adjusted EPS $2.11; reported GAAP EPS $0.01 after one-time charges.
Full-year 2025: $447.6B revenue (+12%), adjusted EPS $16.35, reported EPS $13.23. Source: UnitedHealth Group FY 2025 earnings release (SEC EDGAR Jan 27, 2026).
$447.6B
fy revenue
$2.11
q4 adj. eps
88.9%
UHC adj. MCR
the number that mattered
The forward debate is management’s 2026 guide: revenues >$439B and adjusted EPS >$17.75—set against whatever sell-side models you trust.
-
unitedhealth group’s 2026 outlook sent its shares spiraling lower.in late january, the nation’s largest insurer released its financials for the final quarter of 2025. they were on par with consensus expectations and depicted a rising medical cost ratio, which did not surprise anyone. however, when the conversation moved to the current year, the investment community did not like what it heard.
-
a floor for earnings was set at $17.75 a share, as management highlighted a strategic pivot toward margin improvement that would result in a vs. prior year top-line decline.
-
all told, management set the 2026 revenue bar at $439 billion.
-
the medical cost ratio was estimated to be 88.8% for 2026, give or take 50 basis points in each direction, working off a membership base that was apt to slide down to somewhere between 46.9 million and 47.5 million lives. (came in at 49.8 million to close 2025).
-
much of the membership culling is expected on the medicare advantage and medicaid fronts.for our part, we think the $439 billion is a worst-case scenario and are placing our top-line call about $5 billion higher, with share earnings targeted at $17.85.
source: UnitedHealth Group FY 2025 earnings release — SEC EDGAR (q42025er992.htm, Jan 27, 2026)
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is medical cost inflation inside medicare advantage and medicaid.
med
medical cost ratio stays above plan
management guided to an 88.8% medical cost ratio for 2026. in human-speak: 88.8 cents of every premium dollar would go out to pay care costs before admin costs, interest, or profit get their turn.
with a 3.9% net margin last year and 2.1% last quarter, even a small miss here has a big effect on EPS.
med
member pruning reduces revenue faster than costs
management expects much of the cleanup to land in medicare advantage and medicaid. the company already pointed to $439B of 2026 revenue versus $447.6B last year, so shrinkage is part of the plan.
if lower-quality membership leaves faster than the cost base adjusts, you get less revenue without the full margin benefit.
med
antitrust action weakens the integrated model
a ~$265B company touching insurance, pharmacy, care delivery, and analytics was always going to draw attention. that matters because integration is central to why this business is worth owning in the first place.
if regulators force separation or limit coordination across those units, the scale advantage gets less valuable and the bull case gets thinner.
med
thin margins turn small misses into big earnings moves
$447.6B of revenue sounds comforting until you remember the company kept only 3.9% of it last year. last quarter it kept 2.1%.
small errors in utilization, pricing, reimbursement, or reserve assumptions can hit EPS harder than the revenue base suggests.
if the 88.8% medical cost ratio guide proves too optimistic, the squeeze lands on a business that kept only 3.9% of revenue last year and 2.1% last quarter.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
medical cost ratio versus 88.8%
this is the scoreboard. if the ratio pushes above 88.8%, the reset is still moving the wrong way.
trend
medicare advantage and medicaid membership
you want fewer bad economics, not just fewer members. that distinction is the whole cleanup story.
risk
antitrust investigation headlines
regulatory pressure matters more here than at a plain insurer because the integrated structure is part of the moat.
calendar
next guide against $439B revenue and $17.75 EPS
those are the numbers management put on the board. the next update tells you whether the reset is stabilizing or slipping.
Analyst rankings
short-term outlook
average
momentum score 3 — in human-speak, analysts think the panic phase passed, but the recovery case still needs proof.
risk profile
average
stability score 3 — this is not balance-sheet danger. it is operating-model danger.
chart momentum
average
technical score 3 — the chart is saying prove the reset worked.
earnings predictability
90 / 100
management usually guides with discipline. that is why the recent valuation hit mattered — predictable companies do not get repriced like this without a real reason.
source: institutional data
Institutional activity
1,575 buyers vs. 1,552 sellers in 3q2025. total institutional holdings: 0.7B shares.
source: institutional data
Price targets
3-5 year target range
$223
$502
$293
current price
$363
target midpoint · +24% from current · 3-5yr high: $545 (+85% · 19% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive